Decheng Capital Global Life Sciences Fund IV, L.P. bought CGON

January 29, 2024 · Form 4 insider transaction

Decheng Capital Global Life Sciences Fund IV, L.P. bought 3,628,198 shares of CG Oncology, Inc., a transaction worth N/A. The trade was recorded as conversion of a derivative and disclosed on an SEC Form 4, filed 2 days after the transaction.

Direction
Acquired (buy-side)
Shares
3,628,198
Price
N/A
Total value
N/A
Role10% owner
SecurityCommon Stock
Transaction codeC: Conversion of a derivative
Transaction dateJanuary 29, 2024
Filing dateJanuary 31, 2024
Shares owned after4,558,812
OwnershipDirect
10b5-1 planNo
AmendedNo

Footnotes

Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering.; These securities are held directly by Decheng Capital Global Life Sciences Fund IV, L.P. ("Fund IV"). Decheng Capital Management IV (Cayman), LLC ("GP IV") is the general partner of Fund IV. Xiangmin Cui is the manager of GP IV. Each of Fund IV, GP IV and Dr. Cui may be deemed to beneficially own the securities held by Fund IV. Each of GP IV and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.

View the original Form 4 on SEC EDGAR